|Drugs covered and range of cutoff concentrations. Note that some drugs are identified based on the presence of unique drug metabolites not listed below.
||Range of Cutoff Concentrations
buprenorphine, codeine, fentanyl, heroin (6-acetylmorphine), dihydrocodeine, hydrocodone, hydromorphone, meperidine, methadone, morphine, naloxone, naltrexone, oxycodone, oxymorphone, propoxyphene, tapentadol, tramadol
amphetamine, cocaine, methamphetamine, MDMA (Ecstasy), MDEA (Eve), MDA, phentermine
alprazolam, amobarbital, butalbital, clonazepam, diazepam, flunitrazepam, flurazepam,lorazepam, midazolam, nitrazepam, nordiazepam, oxazepam, phenobarbital, secobarbital, temazepam, triazolam, zolpidem
#ExistInterpData>Methodology: Qualitative Liquid Chromatography-Time of Flight Mass Spectrometry
Detection of drugs in umbilical cord tissue is intended to reflect maternal drug use during pregnancy. The pattern and frequency of drug(s) used by the mother cannot be determined by this test. A negative result does not exclude the possibility that a mother used drugs during pregnancy. Detection of drugs in umbilical cord tissue depends on extent of maternal drug use, as well as drug stability, unique characteristics of drug deposition in umbilical cord tissue, and the performance of the analytical method. Drugs administered during labor and delivery may be detected. Detection of drugs in umbilical cord tissue does not insinuate impairment and may not affect outcomes for the infant. Interpretive questions should be directed to the laboratory. Glucuronide metabolites are indicated as -G.
For medical purposes only; not valid for forensic use unless testing was performed within Chain of Custody process.
||Absolute Minimum: 6 inches
||80100 x2 (HCPCS: G0431)
||Drug Screen, Targeted, Serum or Plasma, Drugs of Abuse Panel, Meconium - Screen with Reflex to Confirmation/Quantitation